Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/21884
Full metadata record
DC FieldValueLanguage
dc.contributor.authorBrown, Helen-
dc.contributor.authorVansteenkiste, Johan-
dc.contributor.authorNakagawa, Kazuhiko-
dc.contributor.authorCobo, Manuel-
dc.contributor.authorJohn, Thomas-
dc.contributor.authorBarker, Craig-
dc.contributor.authorKohlmann, Alexander-
dc.contributor.authorTodd, Alexander-
dc.contributor.authorSaggese, Matilde-
dc.contributor.authorChmielecki, Juliann-
dc.contributor.authorMarkovets, Aleksandra-
dc.contributor.authorScott, Marietta-
dc.contributor.authorRamalingam, Suresh S-
dc.date2019-10-09-
dc.date.accessioned2019-10-14T04:15:37Z-
dc.date.available2019-10-14T04:15:37Z-
dc.date.issued2019-10-09-
dc.identifier.citationJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2019; online first: 9 October-
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/21884-
dc.description.abstractEpidermal growth factor receptor mutated (EGFRm) non-small cell lung cancer (NSCLC) tumors occasionally express programmed cell death ligand 1 (PD-L1), though frequency and clinical-relevance are not fully characterized. We report PD-L1 expression in patients with EGFRm advanced NSCLC and association with clinical outcomes following treatment with osimertinib or comparator EGFR tyrosine kinase inhibitors in the FLAURA trial (phase III, NCT02296125). Of 231 tissue blocks available from the screened population (including EGFRm positive and negative samples), 197 had sufficient tissue for PD-L1 testing using the SP263 (Ventana) immunohistochemical assay. Tumor cell (TC) staining thresholds of PD-L1 TC≥1%, TC≥25% and TC≥50% were applied. Progression-free survival (PFS) was investigator-assessed, per RECIST 1.1, according to PD-L1 expressors (TC≥1%) or negatives (TC<1%) in randomized patients. PD-L1 staining was successful in 193/197 patient FFPE blocks; of these 128/193 were EGFRm positive and 106/128 patients were randomized to treatment (osimertinib: 54; comparator: 52). At PD-L1 TC≥25% threshold, 8% (10/128) of EGFRm positive tumors expressed PD-L1 versus 35% (23/65) of EGFRm negative tumors. With TC≥1% threshold, 51% (65/128) versus 68% (44/65) were mutation positive and negative respectively, and with the TC≥50% threshold, 5% (7/128) versus 28% (18/65), were mutation positive and negative, respectively. For PD-L1 expressors (TC≥1%), median PFS was 18.4 months with osimertinib and 6.9 months with comparator (HR 0.30 [95% CI: 0.15-0.60]). For PD-L1 negative patients (TC<1%), median PFS was 18.9 months with osimertinib and 10.9 months with comparator (HR 0.37 [95% CI: 0.17-0.74]). Clinical benefit with osimertinib was unaffected by PD-L1 expression status.-
dc.language.isoeng-
dc.subjectEGFRm-
dc.subjectFLAURA-
dc.subjectNSCLC-
dc.subjectOsimertinib-
dc.subjectPD-L1-
dc.titleBrief Report: Programmed Cell Death Ligand 1 Expression in Untreated EGFR Mutated Advanced Non-Small Cell Lung Cancer and Response to Osimertinib versus Comparator in FLAURA.-
dc.typeJournal Article-
dc.identifier.journaltitleJournal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer-
dc.identifier.affiliationPrecision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom-
dc.identifier.affiliationOlivia Newton-John Cancer Research Institute, Heidelberg, Victoria, Australiaen
dc.identifier.affiliationRespiratory Oncology Unit (Respiratory Diseases), University Hospital KU Leuven, Leuven, Belgium-
dc.identifier.affiliationDepartment of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan-
dc.identifier.affiliationMedical Oncology Department, University Regional Hospital of Málaga, IBIMA, Málaga, Spain-
dc.identifier.affiliationPrecision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom-
dc.identifier.affiliationOncology Biometrics, Oncology, AstraZeneca, Cambridge, United Kingdom-
dc.identifier.affiliationGlobal Medicines Development, Oncology, AstraZeneca, Cambridge, United Kingdom-
dc.identifier.affiliationTranslational Medicine, Oncology, AstraZeneca, Waltham, Massachusetts-
dc.identifier.affiliationPrecision Medicine, Oncology R&D, AstraZeneca, Cambridge, United Kingdom-
dc.identifier.affiliationEmory University School of Medicine, Winship Cancer Institute, Atlanta, Georgia-
dc.identifier.affiliationAustin Health, Heidelberg, Victoria, Australia-
dc.identifier.doi10.1016/j.jtho.2019.09.009-
dc.identifier.pubmedid31605792-
dc.type.austinJournal Article-
local.name.researcherJohn, Thomas
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptOlivia Newton-John Cancer Research Institute-
crisitem.author.deptMedical Oncology-
crisitem.author.deptOlivia Newton-John Cancer Wellness and Research Centre-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.